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Abstract:
Objectives: The aim of this case-crossover study was to apply 
association rule analysis to ascertain drug combinations contributing to 
the risk of acute kidney injury (AKI) in adults aged 65 years and older. 
Method: We sourced a nationwide representative sample of New 
Zealanders aged ≥65 years from the pharmaceutical collections and 
hospital discharge information. We classified medication exposure, as a 
binary variable, at individual drug level belonging to medication classes 
including antimicrobials, antihistamines, diuretics, opioids, non-steroidal 
anti-inflammatory medications. We extracted the first-time coded 
diagnosis of AKI from the hospital discharge information. We set up a 
case-crossover cohort, indexed at the first AKI event. Association rules 
were then applied to identify frequent drug combinations in the case and 
the control periods (l-day with a 35-day washout period), and the 
association of AKI with each frequent drug combination was tested by 
computing a matched odds-ratio (MOR) and its 95% confidence interval 
(CI). 
Results: We identified 55747 individuals (mean age 82.14) from 2005 to 
2014 with incident AKI and exposed to at least one of the drugs of 
interest. The frequently used medicines associated with AKI are 
trimethoprim (MOR=1.68; 95%CI= [1.54-1.80]), ondansetron 
(MOR=1.43; 95%CI= [1.25-1.64]), codeine phosphate plus 
metoclopramide (MOR=1.37; 95%CI= [1.11-1.63]), and norfloxacin 
(MOR=1.24; 95%CI [1.05-1.42]). 
Conclusion: We applied association rules, a novel methodology, to big 
data to ascertain drug combinations associated with AKI. Association 
rules uncovered previously implicated medication classes that increase 
the risk of AKI in older adults. The finding that ondansetron increases 
the risk of AKI requires further investigation.
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16 Key points:
17 1. Older adults are at an increased risk of acute kidney injury (AKI) because of aging, 
18 multiple comorbidities, and polypharmacy.
19 2. The association rules method revealed that frequently used drug combinations associated 
20 with AKI are trimethoprim, ondansetron, codeine phosphate plus metoclopramide, and 
21 norfloxacin.
22 3. The study has important implications for advancing geriatric pharmacoepidemiology 
23 research and medication safety in older people.
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2 Background: Older adults are at an increased risk of AKI because of aging, multiple 
3 comorbidities, and polypharmacy.
4 Objectives: The aim of this case-crossover study was to apply association rule analysis to 
5 ascertain drug combinations contributing to the risk of acute kidney injury (AKI) in adults aged 
6 65 years and older.
7 Method: We sourced a nationwide representative sample of New Zealanders aged ≥65 years 
8 from the pharmaceutical collections and hospital discharge information. Prescription records 
9 (2005-2015) of drugs of interest were sourced from New Zealand pharmaceutical collections 
10 (Pharms). We classified medication exposure, as a binary variable, at individual drug level 
11 belonging to medication classes including antimicrobials, antihistamines, diuretics, opioids, 
12 non-steroidal anti-inflammatory medications. Several studies have associated the drugs of 
13 interest from these medication classes with AKI in older adults. We extracted the first-time 
14 coded diagnosis of AKI from the National Minimal Dataset (NMDS). A unique patient 
15 identifier linked the prescription dataset to the event dataset, to set up a case-crossover cohort, 
16 indexed at the first AKI event. Association rules were then applied to identify frequent drug 
17 combinations in the case and the control periods (l-day with a 35-day washout period), and the 
18 association of AKI with each frequent drug combination was tested by computing a matched 
19 odds-ratio (MOR) and its 95% confidence interval (CI). 
20 Results: We identified 55747 individuals (mean age 82.14) from 2005 to 2014 with incident 
21 AKI and exposed to at least one of the drugs of interest. Association rules identified several 
22 medication classes including antimicrobials, nonsteroidal anti-inflammatory drugs and opioids 
23 are associated with AKI. The frequently used medicines associated with AKI are trimethoprim 
24 (MOR=1.68; 95%CI= [1.54-1.80]), ondansetron (MOR=1.43; 95%CI= [1.25-1.64]), codeine 
25 phosphate plus metoclopramide (MOR=1.37; 95%CI= [1.11-1.63]), and norfloxacin 
26 (MOR=1.24; 95%CI [1.05-1.42]).
27 Conclusion: We applied association rules, a novel methodology, to big data to ascertain drug 
28 combinations associated with AKI. Association rules uncovered previously implicated 
29 medication classes that increase the risk of AKI in older adults. The finding that ondansetron 
30 increases the risk of AKI requires further investigation.
31
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1 1. Introduction 
2
3 The association rules (AR) method is regarded as a novel pharmacovigilance tool to investigate 
4 frequent medication and medication combinations contributing to adverse drug events (ADEs) 
5 (1, 2). AR method is applied widely in pharmacoepidemiological studies to evaluate the 
6 complexity of medication combinations and medical comorbidities in older adults, identifying 
7 drug interactions and for post-marketing surveillance of vaccine safety (3-5). AR method is 
8 also used in the field of bioinformatics to identify transcription factors that control gene 
9 transcription (6). This method has also been applied to optimise the selection of clinical 
10 pathways in the management of chronic diseases (7).  Recent studies have demonstrated the 
11 utility of AR in detecting ADEs in older adults. We previously have demonstrated the utility 
12 of the AR method to investigate medication patterns associated with fracture risk in older adults 
13 (8).  To our knowledge, there are no published studies that have applied the AR method 
14 specifically investigate medicines contributing to acute kidney injury in older adults.
15 Acute kidney injury (AKI) is associated with higher morbidity, increased mortality, length of 
16 hospital stay and higher hospital costs (9). Older adults are at an increased risk of AKI because 
17 of aging, multiple comorbidities, and polypharmacy (10). Medication-induced AKI is a 
18 modifiable risk factor, and studies have shown several individual medications can contribute 
19 to AKI (11-13).  Some of the most common medications associated with AKI include 
20 furosemide, metformin, vancomycin and non-steroidal anti-inflammatory drugs (14-16). AKI 
21 in older adults is associated with an increased risk of mortality, lower health-related quality of 
22 life and increased length of hospital stay (17, 18).A systematic review of the literature 
23 concluded that the quality of evidence of medication combinations and their association with 
24 the development of AKI is weak (19). In addition, there is limited population-level evidence 
25 available on the medication combinations associated with AKI. 
26 In this study, we chose to apply AR method to a case-crossover design as it mitigates 
27 confounding from unknown time-invariant confounders. To ensure that a case crossover design 
28 will answer our research question we followed all the recommendations stipulated for the 
29 application of a case crossover design to our analyses (20). For case crossover designs, the key 
30 assumptions are that occurrence of the event must be acute and the exposure must be transient.  
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1 The overarching aim of this case-crossover study was to apply the AR method to ascertain 
2 patterns of medication combinations contributing to the risk of AKI in older adults aged 65 
3 years and older.
4 2. Methodology
5 We obtained ethical approval from the Human Ethics Research Committee, University of Bath 
6 (approval number EIRA1-2629).
7
8 2.1 Data source
9 The New Zealand (NZ) Ministry of Health holds national collections of community pharmacy 
10 dispensing, hospital discharge details and mortality data details. Pharms is the national 
11 collections of all prescription claims made by community pharmacists. It contains prescriptions 
12 of medicines funded by the Pharmaceutical Management Agency (PHARMAC). PHARMAC 
13 is the New Zealand government agency that decides which pharmaceuticals to publicly fund 
14 in New Zealand, and provides funded access to pharmaceuticals for all New Zealanders. The 
15 National Minimum Data Set (NMDS) is a national collection of public and private hospital 
16 discharge information, including coded clinical data for inpatients and day patients. We have 
17 provided a detailed description of both the datasets previously. We used unique encrypted 
18 National Health Index (NHI) identifiers to cross-match medication exposure data with hospital 
19 events data from NMDS.
20 2.2 Study subject
21 We identified from the NMDS all individuals aged 65 years and above with a diagnosis of 
22 incident AKI between 01/01/2005 and 31/12/2014. We used the ICD-10-AM (The 
23 International Statistical Classification of Diseases and Related Health Problems, Tenth 
24 Revision, Australian Modification) code N17.9 to identify individuals with AKI.
25 Medication exposure
26 We were interested to explore the use of medication combinations hence we conducted the 
27 analysis at the individual medication level. We chose 178 medicines (Appendix 1), funded by 
28 PHARMAC, and the prescription durations for these medicines are typically over a short-term, 
29 in a duration of fortnights supply. We classified medication exposure, as a binary variable, at 
30 individual drug level belonging to medication classes including antimicrobials, antihistamines, 
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1 diuretics, opioids, non-steroidal anti-inflammatory medications. Several studies have 
2 associated the drugs of interest from these medication classes with AKI (13, 21, 22).
3 Case- crossover cohort
4 We created a case-crossover cohort for medication exposures, with two 1-day observation 
5 periods and two 5-week (35 days) washout periods, summed up to a 36-day study period. Case-
6 period is the day before the index date. The control period is the period 2-34 days before the 
7 index date. We chose a two 5-week washout periods based on our previous study as well as the 
8 need to minimise carryover effects and misclassification of medication exposure. We 
9 calculated the duration of each prescription by dividing the total dose supplied by the daily 
10 dose. Together with the prescription dates, we determined whether an individual had non-
11 intermittent exposure to the medications of interests within the case and control periods. We 
12 defined non-intermittent exposure to a medication if the individual was prescribed the 
13 medication for more than 80% of the days within the study period. The 80% cut-off is 
14 considered as a standard measure for medication-adherence in pharmacoepidemiological 
15 studies (i.e. the proportion of days covered ≥ 0.8). 
16 We conducted sensitivity analyses to mitigate medication exposure misclassification. We 
17 selected three control periods for each AKI case, defined at -2 to -4 and -8 days. A shorter time 
18 window accounted for transient as well as intermittent exposures. The second analyses used 
19 case and control periods with a 7-day time window to account for misclassification due to 
20 prolonged medication exposures.
21 The pharmaceutical collections (Pharms) and NMDS data were made available as annual, 
22 CSV-formatted datasets, and the above-mentioned filtering and cohort-construction procedures 
23 were performed using a computer program written in R (3.4.2, R Core Team, 2016).
24 2.2 AR methodology and statistical analysis
25 AR methodology is a data-mining algorithm that extracts from a big dataset frequent and 
26 statistically interesting item sets above a chosen frequency threshold. We applied AR in this 
27 study to identify drugs and drug combinations that are associated with an increased risk of 
28 AKI. In this study, drug combinations including singletons that individuals exposed to with a 
29 frequency of at least 1/200 (0.5%) on the day before the event (i.e. within the case-period) are 
30 the frequent item sets. For each frequent drug combination, the interestingness statistics are the 
31 increased odds of AKI onset due to the exposure.
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1 We expressed the increased odds of AKI onset due to exposures as matched odds-ratio (MOR). 
2 From the case-crossover cohort we identified individuals with exposures to medication 
3 combinations in the case and the control periods. We counted the number of individuals who 
4 were exposed to a medication-combination of interest within the case-period but not the control 
5 period (N1), and within the control-period but not the case-period (N2). The MOR can then be 
6 calculated as N1/ N2, and the variance of log (MOR) can be calculated as (1/ N1) + (1/ N2).
7  
8 We used heat maps to display the strength of association between medication exposures and 
9 AKI. In the heat map, each row represents an exposure combination, and each column 
10 represents a medication that appears at least once in the set of exposure combinations. If a 
11 medication appears in a particular exposure combination, the corresponding grid is colored. 
12 We then mapped the MOR calculations onto the heat map. The color intensity of each row (i.e. 
13 each exposure combination) is proportional to log (MOR) of AKI associated with this 
14 combination. The grid bordered with a blue color in the heat map represents log (MOR) > 0 
15 with a confidence level of 95%.
16
17 3. Results
18 We identified 65238 individuals (mean age 82.14) from 2005 to 2014 with incident AKI and 
19 exposed to at least one of the drugs of interest. Of these, 55,747 had at least one prescription 
20 record of the medication of interest (Appendix 2) within the 72-day study period. The 
21 distribution of ages was slightly skewed towards the higher age group, and there were more 
22 females than males. Majority of them were NZ Europeans, and only a few of them belonged 
23 to the Māori ethnic group (Supplementary Table 1). The frequent medication combinations 
24 stratified by age groups are shown in Table 1.

















Amoxycillin + clavulanic acid 75 283 509 578 461 266 2172
Amoxycillin + clavulanic acid + 
Prednisone
11 54 102 95 66 24 352
Bisacodyl 14 43 83 101 82 67 390
Cetirizine hydrochloride 14 87 177 226 160 105 769
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Ciprofloxacin 33 139 204 225 176 110 887
Codeine phosphate 96 481 806 906 769 470 3528
Codeine phosphate + 
Metoclopramide hydrochloride
10 55 65 78 60 23 291
Codeine phosphate +  Prednisone 7 57 99 111 88 38 400
Codeine phosphate + Zopiclone 9 40 70 85 88 56 348
Colchicine 46 167 242 233 151 81 920
Co-trimoxazole 18 128 189 263 230 156 984
Cyclizine hydrochloride 20 69 65 81 64 21 320
Dexamethasone 31 121 155 101 64 27 499
Diazepam 8 71 120 132 111 63 505
Diclofenac sodium 124 310 414 344 221 90 1503
Dihydrocodeine tartrate 28 101 134 136 94 55 548
Domperidone 41 163 254 298 267 176 1199
Doxycycline hydrochloride 11 62 127 117 108 74 499
Erythromycin ethyl succinate 24 62 87 113 101 71 458
Flucloxacillin sodium 20 105 209 227 215 166 942
Glyceryl trinitrate 49 210 424 592 500 293 2068
Haloperidol 13 68 96 122 137 82 518
Hyoscine N-butylbromide 17 62 104 84 61 40 368
Ibuprofen 24 148 261 303 257 154 1147
Loperamide hydrochloride 52 223 325 364 271 138 1373
Loratadine 16 152 255 287 243 185 1138
Lorazepam 8 106 188 248 237 174 961
Metoclopramide hydrochloride 94 344 504 534 419 247 2142
Metoclopramide hydrochloride + 
Morphine sulphate
19 39 79 86 56 36 315
Miconazole nitrate 4 50 60 89 83 68 354
Morphine hydrochloride 39 103 179 249 194 116 880
Morphine hydrochloride + 
Morphine sulphate
24 37 70 89 64 22 306
Morphine sulphate 70 264 411 450 345 188 1728
Naproxen 16 90 146 115 78 39 484
Nitrofurantoin 6 59 109 164 164 129 631
Norfloxacin 17 68 118 113 124 95 535
Ondansetron 25 137 213 150 99 46 670
Paracetamol with codeine 50 267 468 551 486 278 2100
Prednisone 119 637 1106 1241 987 493 4583
Prednisone + Zopiclone 14 51 90 113 128 70 466
Prochlorperazine 37 128 182 241 236 138 962
Promethazine hydrochloride 7 46 61 89 111 57 371
Quetiapine 7 76 151 202 226 145 807
Risperidone 10 46 126 180 203 142 707
Roxithromycin 18 111 206 200 210 116 861
Page 8 of 34
http://mc.manuscriptcentral.com/pds































































Temazepam 16 87 165 214 228 159 869
Triazolam 14 91 192 289 313 204 1103
Trimethoprim 27 156 292 409 513 340 1737
Zopiclone 79 437 810 982 1016 641 3965
1
2 Association rules revealed 48 frequently used drug combinations that are associated with 
3 AKI (Figure 1). AKI is associated commonly with trimethoprim exposure (MOR=1.68; 
4 95%CI= [1.54-1.80]), ondansetron exposure (MOR=1.43; 95%CI= [1.25-1.64]), norfloxacin 
5 exposure (MOR=1.24; 95%CI [1.05-1.42]), and concomitant exposures to codeine phosphate 
6 and metoclopramide (MOR=1.37; 95%CI= [1.11-1.63]).
7 Sensitivity analyses
8 The sensitivity analyses were repeated with (3-day) and weekly (7-day) time-windows. 
9 (Supplementary Figure S1 and S2)
10 3-day time window: Trimethoprim exposure (MOR=1.57; 95%CI= [1.41-1.72), ondansetron 
11 exposure (MOR=1.44; 95%CI= [1.25-1.63]). 
12 7-day time window: Trimethoprim exposure (MOR=1.20; 95%CI= [1.01-1.38), ondansetron 
13 exposure (MOR=1.49; 95%CI= [1.29-1.68]).
14
15 Discussion
16 In this study, we extended the association rules method to a case-crossover matched cohort of 
17 older people to examine medications exposures frequently associated with AKI. AKI is 
18 associated with higher mortality, and increasing hospitalisations, and no immediate treatment 
19 to reverse AKI exists hence the emphasis remains on identifying and avoiding medicines that 
20 are nephrotoxic (23). 
21 Association rules identified several medication classes including antimicrobials, nonsteroidal 
22 anti-inflammatory drugs (NSAIDs) and opioids increase the risk of AKI. Antimicrobials, 
23 ranked in order of increasing MOR, included trimethoprim, co-trimoxazole, norfloxacin, 
24 erythromycin, ciprofloxacin, roxithromycin, nitrofurantoin and flucloxacillin. The finding that 
25 trimethoprim (MOR=1.68; 95%CI= [1.54-1.80]),  poses the highest risk of AKI among the 
26 antimicrobial class is supported by evidence from another population-level cohort study 
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1 conducted in older adults using the UK primary care database, Clinical Practice Research 
2 Datalink (24). This UK study found that trimethoprim (adjusted OR 1.72, 95% CI 1.31 to 2.24) 
3 and ciprofloxacin (adjusted OR 1.48, 95% CI 1.03 to 2.13) increased the odds of AKI compared 
4 with amoxicillin.
5 The association rules method also revealed NSAIDs increase the risk of AKI. NSAIDs, ranked 
6 in order of increasing MOR, included ibuprofen, diclofenac and naproxen. This finding is 
7 consistent with finding from meta-analyses of systematic reviews that showed older people in 
8 the general population exposed to non-selective NSAIDs were at higher risk of AKI (OR 2.51, 
9 95%CI 1.52 to 2.68) compared to younger age groups (12).
10 The finding that morphine increases the risk of AKI in older adults is biologically plausible 
11 and congruent with evidence that links opioid use with AKI. The mechanism that opioids may 
12 increase the risk of AKI involves complex interaction within the autonomic nervous system, 
13 the renin–angiotensin–aldosterone system and anti-diuretic hormone. In addition, dehydration, 
14 rhabdomyolysis and urinary retention during opioid exposure can all increase the risk of AKI 
15 (25).
16 The finding that ondansetron increases the risk of AKI requires further investigation. Limited 
17 data are available regarding the actual incidence and severity of harm resulting from 
18 ondansetron–associated AKI. One study found that co-administration of ondansetron increased 
19 cisplatin nephrotoxicity by inhibition of Multiple Toxin and Extrusion Proteins (MATEs) (26). 
20 MATEs are excretory proteins found in the proximal tubular cells in humans and facilitate 
21 renal excretion of cisplatin. Nephrotoxic potential of co-administration of ondansetron on 
22 clearance of drugs via MATE transporters warrants further investigation. 
23 Our study found combinations of codeine phosphate with metoclopramide, zopiclone, 
24 prednisone, and the medication combination amoxicillin and clavulanic acid increase the risk 
25 of AKI. A systematic review concluded a lack of well-designed studies addressing medication 
26 class combination associated with AKI (19). The systematic review found there is only 
27 evidence to support the combination of NSAIDs and diuretics with or without additional renin-
28 angiotensin aldosterone agents, contributing to AKI, but the evidence to support other 
29 medication combinations with AKI is inadequate.
30 The sensitivity analyses repeated with (3-day) and weekly (7-day) time-windows did not 
31 change the results for trimethoprim and ondansetron. These time windows were chosen to align 
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1 with the best practice recommendations for conducting a case-crossover study. The sensitivity 
2 analyses confirmed that trimethoprim and ondansetron are associated with AKI in older adults. 
3 We did not find effect sizes for codeine phosphate plus metoclopramide and norfloxacin as 
4 only fewer individuals in the study cohort were exposed to these medicines.
5 Strengths
6 This study exemplifies the role of the association rules method to identify interesting 
7 medication combinations across a population linked with AKI. The AR method provides 
8 tremendous opportunities for rapidly generating safety data on medicines and their 
9 combinations in a real-world population setting and regulatory agencies could benefit from this 
10 methodology to monitor for adverse drug events. This study has important implications for 
11 pharmacoepidemiology research, and to advance medication safety surveillance in older people 
12 invariably underrepresented in clinical trials and current pharmacovigilance tools may be 
13 inadequate to uncover important medication combinations contributing to adverse drug events.
14 Limitations
15 The use of a case-crossover cohort mitigates confounding from known and measurable 
16 confounders such as age, sex, ethnicity and chronic comorbidities. However, we recognise that 
17 there is a possibility of confounding by indication due to acute changes in health status, for 
18 example, dehydration that may increase the risk of AKI. We mitigated time-varying 
19 confounding as we employed a short study duration in our analyses, but residual confounding 
20 remains a concern. Our findings are generalisable to older adults but may not be applicable to 
21 younger populations who may have different medications and comorbidity patterns. We 
22 employed prescriptions claims as a marker of medication use, and we did not confirm 
23 medication consumption, overall utilisation was likely to be overestimated. Pharmacy claims 
24 data also lack information about self-medication and the use of over-the-counter drugs such as 
25 NSAIDs and this can result in medication exposure misclassification.  Since our study has 
26 identified medication exposures form community pharmacy claims data the findings may not 
27 be generalisable to other countries where drug formularies and coverage for drug insurance 
28 vary. 
29 In the spirit of following the recommendations and assumptions for implementing a case-
30 crossover design as proposed by Maclure and colleagues (20), we included only transient 
31 medication exposures to represent medication exposure during the time at risk of AKI. We 
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1 acknowledge this is a strength as a well a methodological limitation trying to fulfill the pre-
2 requisite of transient exposure for implementing a case crossover design, as we were not able 
3 to uncover AKI contributed by chronic medication exposures.  For example, in a nested case-
4 control study conducted by Huerta et al. an increased risk of AKI was reported with the 
5 combination of a diuretic and NSAID (27). We met the assumptions that the outcome of interest 
6 must be an acute event and not change over time; AKI is an acute event and is unlikely to 
7 change over the short study period employed in our study.
8 Conclusion: We applied association rules, a novel methodology, to big data to ascertain 
9 medication combinations associated with adverse drug events. Association rules uncovered 
10 previously implicated medication classes such as antimicrobials, opioids, NSAIDs that 
11 increase the risk of AKI in older adults. The finding that ondansetron increases the risk of AKI 
12 requires further investigation. In the future, we intend to develop the AR algorithm as Artificial 
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12 Figure 1: Heat map showing medication-exposure combinations and the MOR of AKI due to 
13 case-period exposures (one-day time window) and the statistical significance.
14 Supplementary Figure S1: Heat map showing medication-exposure combinations and the 
15 MOR of AKI due to case-period exposures (3-day time window) and the statistical 
16 significance.
17 Supplementary Figure S2:  Heat map showing medication-exposure combinations and the 
18 MOR of AKI due to case-period exposures (7-day time window) and the statistical 
19 significance.
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1 Predicting Identifying frequent drug combinations associated with acute 
2 kidney injury in older adults using association rules method
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16 Key points:
17 1. Older adults are at an increased risk of acute kidney injury (AKI) because of aging, 
18 multiple comorbidities, and polypharmacy.
19 2. The association rules method revealed that frequently used drug combinations associated 
20 with AKI are trimethoprim, ondansetron, codeine phosphate plus metoclopramide, and 
21 norfloxacin.
22 3. The study has important implications for advancing geriatric pharmacoepidemiology 
23 research and medication safety in older people.
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2 Background: Older adults are at an increased risk of AKI because of aging, multiple 
3 comorbidities, and polypharmacy.
4 Objectives: The aim of this case-crossover study was to apply association rule analysis to 
5 ascertain drug combinations contributing to the risk of acute kidney injury (AKI) in adults aged 
6 65 years and older.
7 Method: We sourced a nationwide representative sample of New Zealanders aged ≥65 years 
8 from the pharmaceutical collections and hospital discharge information. Prescription records 
9 (2005-2015) of drugs of interest were sourced from New Zealand pharmaceutical collections 
10 (Pharms). We classified medication exposure, as a binary variable, at individual drug level 
11 belonging to medication classes including antimicrobials, antihistamines, diuretics, opioids, 
12 non-steroidal anti-inflammatory medications. Several studies have associated the drugs of 
13 interest from these medication classes with AKI in older adults. We extracted the first-time 
14 coded diagnosis of AKI from the National Minimal Dataset (NMDS). A unique patient 
15 identifier linked the prescription dataset to the event dataset, to set up a case-crossover cohort, 
16 indexed at the first AKI event. Association rules were then applied to identify frequent drug 
17 combinations in the case and the control periods (l-day with a 35-day washout period), and the 
18 association of AKI with each frequent drug combination was tested by computing a matched 
19 odds-ratio (MOR) and its 95% confidence interval (CI). 
20 Results: We identified 55747 individuals (mean age 82.14) from 2005 to 2014 with incident 
21 AKI and exposed to at least one of the drugs of interest. Association rules identified several 
22 medication classes including antimicrobials, nonsteroidal anti-inflammatory drugs and opioids 
23 are associated with AKI. The frequently used medicines associated with AKI are trimethoprim 
24 (MOR=1.68; 95%CI= [1.54-1.80]), ondansetron (MOR=1.43; 95%CI= [1.25-1.64]), codeine 
25 phosphate plus metoclopramide (MOR=1.37; 95%CI= [1.11-1.63]), and norfloxacin 
26 (MOR=1.24; 95%CI [1.05-1.42]).
27 Conclusion: We applied association rules, a novel methodology, to big data to ascertain drug 
28 combinations associated with AKI. Association rules uncovered previously implicated 
29 medication classes that increase the risk of AKI in older adults. The finding that ondansetron 
30 increases the risk of AKI requires further investigation.
31
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1 1. Introduction 
2
3 The association rules (AR) method is regarded as a novel pharmacovigilance tool to investigate 
4 frequent medication and medication combinations contributing to adverse drug events (ADEs) 
5 (1, 2). AR method is applied widely in pharmacoepidemiological studies to evaluate the 
6 complexity of medication combinations and medical comorbidities in older adults, identifying 
7 drug interactions and for post-marketing surveillance of vaccine safety (3-5). AR method is 
8 also used in the field of bioinformatics to identify transcription factors that control gene 
9 transcription (6). This method has also been applied to optimise the selection of clinical 
10 pathways in the management of chronic diseases (7).  Recent studies have demonstrated the 
11 utility of AR in detecting ADEs in older adults. We previously have demonstrated the utility 
12 of the AR method to investigate medication patterns associated with fracture risk in older adults 
13 (8).  To our knowledge, there are no published studies that have applied the AR method 
14 specifically investigate medicines contributing to acute kidney injury in older adults.
15 Acute kidney injury (AKI) is associated with higher morbidity, increased mortality, length of 
16 hospital stay and higher hospital costs (9). Older adults are at an increased risk of AKI because 
17 of aging, multiple comorbidities, and polypharmacy (10). Medication-induced AKI is a 
18 modifiable risk factor, and studies have shown several individual medications can contribute 
19 to AKI (11-13).  Some of the most common medications associated with AKI include 
20 furosemide, metformin, vancomycin and non-steroidal anti-inflammatory drugs (14-16). AKI 
21 in older adults is associated with an increased risk of mortality, lower health-related quality of 
22 life and increased length of hospital stay (17, 18).A systematic review of the literature 
23 concluded that the quality of evidence of medication combinations and their association with 
24 the development of AKI is weak (19). In addition, there is limited population-level evidence 
25 available on the medication combinations associated with AKI. 
26 In this study, we chose to apply AR method to a case-crossover design as it mitigates 
27 confounding from unknown time-invariant confounders. To ensure that a case crossover design 
28 will answer our research question we followed all the recommendations stipulated for the 
29 application of a case crossover design to our analyses (20). For case crossover designs, the key 
30 assumptions are that occurrence of the event must be acute and the exposure must be transient.  
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1 The overarching aim of this case-crossover study was to apply the AR method to ascertain 
2 patterns of medication combinations contributing to the risk of AKI in older adults aged 65 
3 years and older.
4 2. Methodology
5 We obtained ethical approval from the Human Ethics Research Committee, University of Bath 
6 (approval number EIRA1-2629).
7
8 2.1 Data source
9 The New Zealand (NZ) Ministry of Health holds national collections of community pharmacy 
10 dispensing, hospital discharge details and mortality data details. Pharms is the national 
11 collections of all prescription claims made by community pharmacists. It contains prescriptions 
12 of medicines funded by the Pharmaceutical Management Agency (PHARMAC). PHARMAC 
13 is the New Zealand government agency that decides which pharmaceuticals to publicly fund 
14 in New Zealand, and provides funded access to pharmaceuticals for all New Zealanders. The 
15 National Minimum Data Set (NMDS) is a national collection of public and private hospital 
16 discharge information, including coded clinical data for inpatients and day patients. We have 
17 provided a detailed description of both the datasets previously. We used unique encrypted 
18 National Health Index (NHI) identifiers to cross-match medication exposure data with hospital 
19 events data from NMDS.
20 2.2 Study subject
21 We identified from the NMDS all individuals aged 65 years and above with a diagnosis of 
22 incident AKI between 01/01/2005 and 31/12/2014. We used the ICD-10-AM (The 
23 International Statistical Classification of Diseases and Related Health Problems, Tenth 
24 Revision, Australian Modification) code N17.9 to identify individuals with AKI.
25 Medication exposure
26 We were interested to explore the use of medication combinations hence we conducted the 
27 analysis at the individual medication level. We chose 178 medicines (Appendix 1), funded by 
28 PHARMAC, and the prescription durations for these medicines are typically over a short-term, 
29 in a duration of fortnights supply. We classified medication exposure, as a binary variable, at 
30 individual drug level belonging to medication classes including antimicrobials, antihistamines, 
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1 diuretics, opioids, non-steroidal anti-inflammatory medications. Several studies have 
2 associated the drugs of interest from these medication classes with AKI (13, 21, 22).
3 Case- crossover cohort
4 We created a case-crossover cohort for medication exposures, with two 1-day observation 
5 periods and two 5-week (35 days) washout periods, summed up to a 36-day study 
6 period(Figure 1). Case-period is the day before the index date. The control period is the period 
7 2-34 days before the index date. We chose a two 5-week washout periods based on our previous 
8 study as well as the need to minimise carryover effects and misclassification of medication 
9 exposure. We calculated the duration of each prescription by dividing the total dose supplied 
10 by the daily dose. Together with the prescription dates, we determined whether an individual 
11 had non-intermittent exposure to the medications of interests within the case and control 
12 periods. We defined non-intermittent exposure to a medication if the individual was prescribed 
13 the medication for more than 80% of the days within the study period. The 80% cut-off is 
14 considered as a standard measure for medication-adherence in pharmacoepidemiological 
15 studies (i.e. the proportion of days covered ≥ 0.8). 
16 We conducted sensitivity analyses to mitigate medication exposure misclassification. We 
17 selected three control periods for each AKI case, defined at -2 to -4 and -8 days. A shorter time 
18 window accounted for transient as well as intermittent exposures. The second analyses used 
19 case and control periods with a 7-day time window to account for misclassification due to 
20 prolonged medication exposures.
21 The pharmaceutical collections (Pharms) and NMDS data were made available as annual, 
22 CSV-formatted datasets, and the above-mentioned filtering and cohort-construction procedures 
23 were performed using a computer program written in R (3.4.2, R Core Team, 2016).
24 2.2 AR methodology and statistical analysis
25 AR methodology is a data-mining algorithm that extracts from a big dataset frequent and 
26 statistically interesting item sets above a chosen frequency threshold. We applied AR in this 
27 study to identify drugs and drug combinations that are associated with an increased risk of 
28 AKI. In this study, drug combinations including singletons that individuals exposed to with a 
29 frequency of at least 1/200 (0.5%) on the day before the event (i.e. within the case-period) are 
30 the frequent item sets. For each frequent drug combination, the interestingness statistics are the 
31 increased odds of AKI onset due to the exposure.
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1 We expressed the increased odds of AKI onset due to exposures as matched odds-ratio (MOR). 
2 From the case-crossover cohort we identified individuals with exposures to medication 
3 combinations in the case and the control periods. We counted the number of individuals who 
4 were exposed to a medication-combination of interest within the case-period but not the control 
5 period (N1), and within the control-period but not the case-period (N2). The MOR can then be 
6 calculated as N1/ N2, and the variance of log (MOR) can be calculated as (1/ N1) + (1/ N2).
7  
8 We used heat maps to display the strength of association between medication exposures and 
9 AKI. In the heat map, each row represents an exposure combination, and each column 
10 represents a medication that appears at least once in the set of exposure combinations. If a 
11 medication appears in a particular exposure combination, the corresponding grid is colored. 
12 We then mapped the MOR calculations onto the heat map. The color intensity of each row (i.e. 
13 each exposure combination) is proportional to log (MOR) of AKI associated with this 
14 combination. The grid bordered with a blue color in the heat map represents log (MOR) > 0 
15 with a confidence level of 95%.
16
17 3. Results
18 We identified 65238 individuals (mean age 82.14) from 2005 to 2014 with incident AKI and 
19 exposed to at least one of the drugs of interest. Of these, 55,747 had at least one prescription 
20 record of the medication of interest (Appendix 2) within the 72-day study period. The 
21 distribution of ages was slightly skewed towards the higher age group, and there were more 
22 females than males. Majority of them were NZ Europeans, and only a few of them belonged 
23 to the Māori ethnic group (Supplementary Table 1). The frequent medication combinations 
24 stratified by age groups are shown in Table 1.

















Amoxycillin + clavulanic acid 75 283 509 578 461 266 2172
Amoxycillin + clavulanic acid + 
Prednisone
11 54 102 95 66 24 352
Bisacodyl 14 43 83 101 82 67 390
Cetirizine hydrochloride 14 87 177 226 160 105 769
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Ciprofloxacin 33 139 204 225 176 110 887
Codeine phosphate 96 481 806 906 769 470 3528
Codeine phosphate + 
Metoclopramide hydrochloride
10 55 65 78 60 23 291
Codeine phosphate +  Prednisone 7 57 99 111 88 38 400
Codeine phosphate + Zopiclone 9 40 70 85 88 56 348
Colchicine 46 167 242 233 151 81 920
Co-trimoxazole 18 128 189 263 230 156 984
Cyclizine hydrochloride 20 69 65 81 64 21 320
Dexamethasone 31 121 155 101 64 27 499
Diazepam 8 71 120 132 111 63 505
Diclofenac sodium 124 310 414 344 221 90 1503
Dihydrocodeine tartrate 28 101 134 136 94 55 548
Domperidone 41 163 254 298 267 176 1199
Doxycycline hydrochloride 11 62 127 117 108 74 499
Erythromycin ethyl succinate 24 62 87 113 101 71 458
Flucloxacillin sodium 20 105 209 227 215 166 942
Glyceryl trinitrate 49 210 424 592 500 293 2068
Haloperidol 13 68 96 122 137 82 518
Hyoscine N-butylbromide 17 62 104 84 61 40 368
Ibuprofen 24 148 261 303 257 154 1147
Loperamide hydrochloride 52 223 325 364 271 138 1373
Loratadine 16 152 255 287 243 185 1138
Lorazepam 8 106 188 248 237 174 961
Metoclopramide hydrochloride 94 344 504 534 419 247 2142
Metoclopramide hydrochloride + 
Morphine sulphate
19 39 79 86 56 36 315
Miconazole nitrate 4 50 60 89 83 68 354
Morphine hydrochloride 39 103 179 249 194 116 880
Morphine hydrochloride + 
Morphine sulphate
24 37 70 89 64 22 306
Morphine sulphate 70 264 411 450 345 188 1728
Naproxen 16 90 146 115 78 39 484
Nitrofurantoin 6 59 109 164 164 129 631
Norfloxacin 17 68 118 113 124 95 535
Ondansetron 25 137 213 150 99 46 670
Paracetamol with codeine 50 267 468 551 486 278 2100
Prednisone 119 637 1106 1241 987 493 4583
Prednisone + Zopiclone 14 51 90 113 128 70 466
Prochlorperazine 37 128 182 241 236 138 962
Promethazine hydrochloride 7 46 61 89 111 57 371
Quetiapine 7 76 151 202 226 145 807
Risperidone 10 46 126 180 203 142 707
Roxithromycin 18 111 206 200 210 116 861
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Temazepam 16 87 165 214 228 159 869
Triazolam 14 91 192 289 313 204 1103
Trimethoprim 27 156 292 409 513 340 1737
Zopiclone 79 437 810 982 1016 641 3965
1













Asian 48 235 408 353 239 120
MELAA 5 15 33 39 30 12
Māori 363 1109 1231 809 317 119
NZ-European 1217 5358 9749 12057 11096 6907
Other 54 206 371 432 377 266
Pacific 169 506 701 460 251 85
Female 739 3017 5236 6604 6375 4522
Male 1117 4412 7257 7546 5935 2987
3
4 Association rules revealed 48 frequently used drug combinations that are associated with 
5 AKI (Figure 12). AKI is associated commonly with trimethoprim exposure (MOR=1.68; 
6 95%CI= [1.54-1.80]), ondansetron exposure (MOR=1.43; 95%CI= [1.25-1.64]), norfloxacin 
7 exposure (MOR=1.24; 95%CI [1.05-1.42]), and concomitant exposures to codeine phosphate 
8 and metoclopramide (MOR=1.37; 95%CI= [1.11-1.63]).
9 Sensitivity analyses
10 The sensitivity analyses were repeated with (3-day) and weekly (7-day) time-windows. 
11 (Supplementary Figure S1 and S2)
12 3-day time window: Trimethoprim exposure (MOR=1.57; 95%CI= [1.41-1.72), ondansetron 
13 exposure (MOR=1.44; 95%CI= [1.25-1.63]). 
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1 7-day time window: Trimethoprim exposure (MOR=1.20; 95%CI= [1.01-1.38), ondansetron 
2 exposure (MOR=1.49; 95%CI= [1.29-1.68]).
3
4 Discussion
5 In this study, we extended the association rules method to a case-crossover matched cohort of 
6 older people to examine medications exposures frequently associated with AKI. AKI is 
7 associated with higher mortality, and increasing hospitalisations, and no immediate treatment 
8 to reverse AKI exists hence the emphasis remains on identifying and avoiding medicines that 
9 are nephrotoxic (23). 
10 Association rules identified several medication classes including antimicrobials, nonsteroidal 
11 anti-inflammatory drugs (NSAIDs) and opioids increase the risk of AKI. Antimicrobials, 
12 ranked in order of increasing MOR, included trimethoprim, co-trimoxazole, norfloxacin, 
13 erythromycin, ciprofloxacin, roxithromycin, nitrofurantoin and flucloxacillin. The finding that 
14 trimethoprim (MOR=1.68; 95%CI= [1.54-1.80]),  poses the highest risk of AKI among the 
15 antimicrobial class is supported by evidence from another population-level cohort study 
16 conducted in older adults using the UK primary care database, Clinical Practice Research 
17 Datalink (24). This UK study found that trimethoprim (adjusted OR 1.72, 95% CI 1.31 to 2.24) 
18 and ciprofloxacin (adjusted OR 1.48, 95% CI 1.03 to 2.13) increased the odds of AKI compared 
19 with amoxicillin.
20 The association rules method also revealed NSAIDs increase the risk of AKI. NSAIDs, ranked 
21 in order of increasing MOR, included ibuprofen, diclofenac and naproxen. This finding is 
22 consistent with finding from meta-analyses of systematic reviews that showed older people in 
23 the general population exposed to non-selective NSAIDs were at higher risk of AKI (OR 2.51, 
24 95%CI 1.52 to 2.68) compared to younger age groups (12).
25 The finding that morphine increases the risk of AKI in older adults is biologically plausible 
26 and congruent with evidence that links opioid use with AKI. The mechanism that opioids may 
27 increase the risk of AKI involves complex interaction within the autonomic nervous system, 
28 the renin–angiotensin–aldosterone system and anti-diuretic hormone. In addition, dehydration, 
29 rhabdomyolysis and urinary retention during opioid exposure can all increase the risk of AKI 
30 (25).
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1 The finding that ondansetron increases the risk of AKI requires further investigation. Limited 
2 data are available regarding the actual incidence and severity of harm resulting from 
3 ondansetron–associated AKI. One study found that co-administration of ondansetron increased 
4 cisplatin nephrotoxicity by inhibition of Multiple Toxin and Extrusion Proteins (MATEs) (26). 
5 MATEs are excretory proteins found in the proximal tubular cells in humans and facilitate 
6 renal excretion of cisplatin. Nephrotoxic potential of co-administration of ondansetron on 
7 clearance of drugs via MATE transporters warrants further investigation. 
8 Our study found combinations of codeine phosphate with metoclopramide, zopiclone, 
9 prednisone, and the medication combination amoxicillin and clavulanic acid increase the risk 
10 of AKI. A systematic review concluded a lack of well-designed studies addressing medication 
11 class combination associated with AKI (19). The systematic review found there is only 
12 evidence to support the combination of NSAIDs and diuretics with or without additional renin-
13 angiotensin aldosterone agents, contributing to AKI, but the evidence to support other 
14 medication combinations with AKI is inadequate.
15 The sensitivity analyses repeated with (3-day) and weekly (7-day) time-windows did not 
16 change the overall results for trimethoprim and ondansetron. These time windows were chosen 
17 to align with the best practice recommendations for conducting a case-crossover study. The 
18 sensitivity analyses confirmed that trimethoprim and, ondansetron, codeine phosphate plus 
19 metoclopramide, and norfloxacin are associated with AKI in older adults. We did not find 
20 effect sizes for codeine phosphate plus metoclopramide and norfloxacin as only fewer 
21 individuals in the study cohort were exposed to these medicines.
22 Strengths
23 This study exemplifies the role of the association rules method to identify interesting 
24 medication combinations across a population linked with AKI. The AR method provides 
25 tremendous opportunities for rapidly generating safety data on medicines and their 
26 combinations in a real-world population setting and regulatory agencies could benefit from this 
27 methodology to monitor for adverse drug events. This study has important implications for 
28 pharmacoepidemiology research, and to advance medication safety surveillance in older people 
29 invariably underrepresented in clinical trials and current pharmacovigilance tools may be 
30 inadequate to uncover important medication combinations contributing to adverse drug events.
31 Limitations
Page 26 of 34
http://mc.manuscriptcentral.com/pds































































1 The use of a case-crossover cohort mitigates confounding from known and measurable 
2 confounders such as age, sex, ethnicity and chronic comorbidities. However, we recognise that 
3 there is a possibility of confounding by indication due to acute changes in health status, for 
4 example, dehydration that may increase the risk of AKI. We mitigated time-varying 
5 confounding as we employed a short study duration in our analyses, but residual confounding 
6 remains a concern. Our findings are generalisable as we applied the AR method to the national 
7 population of to older adults but may not be applicable to younger populations who may have 
8 different medications and comorbidity patterns. However, Wwe employed prescriptions claims 
9 as a marker of medication use, and we did not confirm medication consumption, overall 
10 utilisation was likely to be overestimated. Pharmacy claims data also lack information about 
11 self-medication and the use of over-the-counter drugs such as NSAIDs and this can result in 
12 medication exposure misclassification.  Since our study has identified medication exposures 
13 form community pharmacy claims data the findings may not be generalisable to other countries 
14 where drug formularies and coverage for drug insurance vary. 
15 In the spirit of following the recommendations and assumptions for implementing a case-
16 crossover design as proposed by Maclure and colleagues (20), we included only transient 
17 medication exposures to represent medication exposure during the time at risk of AKI. We 
18 acknowledge this is a strength as a well a methodological limitation trying to fulfill the pre-
19 requisite of transient exposure for implementing a case crossover design, as we were not able 
20 to uncover AKI contributed by chronic medication exposures.  For example, in a nested case-
21 control study conducted by Huerta et al. an increased risk of AKI was reported with the 
22 combination of a diuretic and NSAID (27). We met the assumptions that the outcome of interest 
23 must be an acute event and not change over time; AKI is an acute event and is unlikely to 
24 change over the short study period employed in our study.
25 Conclusion: We applied association rules, a novel methodology, to big data to ascertain 
26 medication combinations associated with adverse drug events. Association rules uncovered 
27 previously implicated medication classes such as antimicrobials, opioids, NSAIDs that 
28 increase the risk of AKI in older adults. The finding that ondansetron increases the risk of AKI 
29 requires further investigation. In the future, we intend to develop the AR algorithm as Artificial 
30 Intelligence technology to predict ADRs occurring and aid clinical decision support to the 
31 healthcare provider.
32
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30 Figure 1: Schematic diagram of the case-crossover cohort.
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1 Figure 12: Heat map showing medication-exposure combinations and the MOR of AKI due 
2 to case-period exposures (one-day time window) and the statistical significance.
3 Supplementary Figure S1: Heat map showing medication-exposure combinations and the 
4 MOR of AKI due to case-period exposures (3-day time window) and the statistical 
5 significance.
6 Supplementary Figure S2:  Heat map showing medication-exposure combinations and the 
7 MOR of AKI due to case-period exposures (7-day time window) and the statistical 
8 significance.
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